Imunon, Inc. Investment Income, Net
Imunon, Inc. (IMNN) reported Investment Income, Net of $32.52 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-11
- Imunon, Inc. investment income, net for the quarter ending 2026-06-30 was $32.52K, a 19.09% increase year-over-year.
- Imunon, Inc. investment income, net for the quarter ending 2026-03-31 was $57.53K, a 34.40% increase year-over-year.
- Imunon, Inc. investment income, net for the quarter ending 2025-12-31 was $38.85K, a 56.32% decline year-over-year.
- Imunon, Inc. investment income, net for the quarter ending 2025-09-30 was $46.70K, a 59.74% decline year-over-year.
- Imunon, Inc. investment income, net for fiscal 2025 was $155.67K, a 69.61% decline from fiscal 2024.
- Imunon, Inc. investment income, net for fiscal 2024 was $512.20K, a 55.75% decline from fiscal 2023.
- Imunon, Inc. investment income, net for fiscal 2023 was $1.16M, a 155.35% increase from fiscal 2022.
- Imunon, Inc. investment income, net for fiscal 2022 was $453.36K, a 4022.92% increase from fiscal 2021.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.52K 10-Q · filed 2026-08-11 | $90.05K 10-Q · filed 2026-08-11 | $128.90K derived: sum of 3 quarters · filed 2026-08-11 | $175.60K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $57.53K 10-Q · filed 2026-05-12 | $96.38K derived: sum of 2 quarters · filed 2026-05-12 | $143.09K derived: sum of 3 quarters · filed 2026-05-12 | $170.39K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $38.85K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $85.56K derived: sum of 2 quarters · filed 2026-03-31 | $112.86K derived: sum of 3 quarters · filed 2026-08-11 | $155.67K 10-K · filed 2026-03-31 |
| 2025-09-30 | $46.70K 10-Q · filed 2025-11-13 | $74.01K derived: sum of 2 quarters · filed 2026-08-11 | $116.81K 10-Q · filed 2025-11-13 | $205.77K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $27.30K 10-Q · filed 2026-08-11 | $70.11K 10-Q · filed 2026-08-11 | $159.07K derived: sum of 3 quarters · filed 2026-08-11 | $275.06K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $42.80K 10-Q · filed 2026-05-12 | $131.76K derived: sum of 2 quarters · filed 2026-05-12 | $247.75K derived: sum of 3 quarters · filed 2026-05-12 | $473.09K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $88.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $204.95K derived: sum of 2 quarters · filed 2026-03-31 | $430.28K derived: sum of 3 quarters · filed 2026-03-31 | $512.20K 10-K · filed 2026-03-31 |
| 2024-09-30 | $115.99K 10-Q · filed 2025-11-13 | $341.33K derived: sum of 2 quarters · filed 2025-11-13 | $423.25K 10-Q · filed 2025-11-13 | $618.67K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $225.33K 10-Q · filed 2025-08-05 | $307.25K 10-Q · filed 2025-08-05 | $502.68K derived: sum of 3 quarters · filed 2025-08-05 | $930.14K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $81.92K 10-Q · filed 2025-05-12 | $277.35K derived: sum of 2 quarters · filed 2025-05-12 | $704.80K derived: sum of 3 quarters · filed 2025-05-12 | $986.48K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $195.43K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $622.88K derived: sum of 2 quarters · filed 2025-02-27 | $904.55K derived: sum of 3 quarters · filed 2025-02-27 | $1.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | $427.45K 10-Q · filed 2024-11-07 | $709.13K derived: sum of 2 quarters · filed 2024-11-07 | $962.20K 10-Q · filed 2024-11-07 | $1.21M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $281.67K 10-Q · filed 2024-08-14 | $534.74K 10-Q · filed 2024-08-14 | $782.34K derived: sum of 3 quarters · filed 2024-08-14 | $935.64K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $253.07K 10-Q · filed 2024-05-13 | $500.67K derived: sum of 2 quarters · filed 2024-05-13 | $653.97K derived: sum of 3 quarters · filed 2024-05-13 | $694.32K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $247.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $400.90K derived: sum of 2 quarters · filed 2024-03-28 | $441.25K derived: sum of 3 quarters · filed 2024-03-28 | $453.36K 10-K · filed 2024-03-28 |
| 2022-09-30 | $153.30K 10-Q · filed 2023-11-14 | $193.66K derived: sum of 2 quarters · filed 2023-11-14 | $205.76K 10-Q · filed 2023-11-14 | $211.14K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $40.35K 10-Q · filed 2023-08-10 | $52.46K 10-Q · filed 2023-08-10 | $57.84K derived: sum of 3 quarters · filed 2023-08-10 | $61.39K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $12.10K 10-Q · filed 2023-05-11 | $17.49K derived: sum of 2 quarters · filed 2023-05-11 | $21.04K derived: sum of 3 quarters · filed 2023-05-11 | $20.69K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.38K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $8.93K derived: sum of 2 quarters · filed 2023-03-30 | $8.59K derived: sum of 3 quarters · filed 2023-03-30 | $11.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $3.55K 10-Q · filed 2022-11-14 | $3.20K derived: sum of 2 quarters · filed 2022-11-14 | $5.61K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$349.00 10-Q · filed 2022-08-15 | $2.06K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $2.41K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $119.91K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |